Regula Software Now Supports the Latest Standard for Biometric Passport Verification
With its latest update, Regula Document Reader SDK, a comprehensive software solution for identity document verification, ensures 100% support for the new ISO/IEC 39794-5 standard regulating the methods of facial data storage and verification in e-passport chips. According to the ICAO guidelines, all document readers and verification systems must be compatible with the new standard by 2026, with passport issuers required to fully adopt the new format by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218969889/en/
Regula Document Reader SDK correctly extracts and verifies facial data encoded in the e-passport chip under the new ISO/IEC 39794-5 standard. (Graphic: Regula)
The ISO/IEC 39794-5 standard introduces an enhanced framework for facial image data, significantly improving interoperability, processing speed, and recognition accuracy across different identity verification (IDV) systems worldwide. Unlike the previous ISO/IEC 19794-5:2005 standard, which primarily stored a basic facial image, the new format records additional metadata, including detailed facial landmarks, precise eye and hair color, and other biometric attributes.
Why this matters
The richer set of pre-stored reference points eliminates the need for separate face detection and feature extraction during verification. Instead of calculating key facial points from scratch, IDV systems can use the pre-recorded metadata, accelerating processing times and ensuring consistent, high-quality recognition results—regardless of the local algorithm used for comparison. This standardization guarantees that a person’s face in their passport will be consistently and accurately verified across different countries, improving global interoperability.
Apart from that, the ISO/IEC 39794-5 standard implements a flexible framework for future extensions. This means that as new attributes or enhancements are introduced in the future, all systems supporting this standard will remain fully functional without requiring urgent updates—unlike the current situation, where all IDV systems would need to be updated to accommodate new data formats.
Preparing for the transition
Although the current ISO/IEC 19794-5:2005 will remain valid, the industry has started the transition period, and businesses worldwide should be ready to process the new format data before 2026.
Regula’s long-standing expertise in secure RFID chip reading and trustworthy data verification ensured smooth adaptation to the new standard even prior to its coming into force. The company’s participation in the recent testing event in Australia demonstrated its ability to correctly extract, interpret, and verify biometric facial data encoded according to ISO/IEC 39794-5. This means that identity verification systems using Regula’s software are future-proofed against compatibility issues that could arise as countries transition to the new format.
In addition, the new standard will require organizations from banks to border control to update their passport readers with software that fits this standard. Regula's IDV software is compatible with most document readers on the market and can be easily used with any device model. This implies a seamless transition to the new standard without replacing existing hardware, ensuring a cost-effective and hassle-free upgrade.
“The shift to ISO/IEC 39794-5 is a major step forward in improving compatibility and efficiency in biometric verification. With more detailed metadata now embedded in e-passports, identity verification systems can achieve faster processing and more accurate recognition results. Our expertise in RFID chip processing ensures that Regula’s technology is already fully equipped to support this transition, providing organizations with seamless, future-proof solutions that help them stay in line with regulatory changes,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To get additional information about the latest update to Regula Document Reader SDK, read the technical documentation. If you are interested in learning more about how Regula processes RFID chip data, visit the official website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218969889/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom